Trial Profile

Lenalidomide, Melphalan, Prednisone, and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 11 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Melphalan (Primary) ; Prednisone (Primary) ; Thalidomide (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms RMPT

Most Recent Events

09 May 2016 Status changed from active, no longer recruiting to completed.
18 Mar 2010 Planned end date (Feb 2011) added as reported by ClinicalTrials.gov.
05 Dec 2009 Results presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH 2009).

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com